Abstract
Double-blind trials were conducted in volunteers to evaluate the efficacy of the prophylactic 3,4-dihydro-1-isoquinolineacetamide hydrochloride (DIQA) treatment against rhinovirus type 24 challenge. Ten men received a 7-day course of DIQA treatment and 11 men received a placebo. The intranasal viral challenge dose was 10 mean tissue culture infective doses. The oral administration of 1 g prechallenge and 2 g a day for 6 consecutive postchallenge days did not prevent the development of colds. Nine drug-treated men and 10 controls developed rhinovirus illness. However, the illnesses of the drug-treated men were mild. Rhinorrhea occurred less frequently and was more mild in the drug-treated group. The challenge virus was recovered from 80% of these subjects in both groups, but almost twice the number of challenge viruses were isolated from the controls than from the drug-treated men. The prophylactic DIQA therapy appears to suppress the cold syndrome and to reduce virus excretion, although its effect is marginal. Additional clinical trials are warranted to confirm the antirhinoviral effect of this drug.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Grunberg E., Prince H. N. The antiviral activity of 3,4-dihydro-1-isoquinolineacetamide hydrochloride in vitro, in ovo, and in small laboratory animals. Proc Soc Exp Biol Med. 1968 Nov;129(2):422–430. doi: 10.3181/00379727-129-33335. [DOI] [PubMed] [Google Scholar]
- Larin N. M., Beare A. S., Copping M. P., McDonald C. R., McDougall J. K., Roberts B., Smith J. B. Spectrum and characteristics of the virus-inhibitory action of two isoquinoline derivatives. Antimicrob Agents Chemother (Bethesda) 1967;7:646–653. doi: 10.1128/AAC.7.5.646. [DOI] [PubMed] [Google Scholar]
- Meenan P. N., Hillary I. B. Prophylaxis of influenza B with UK 2054. Lancet. 1969 Sep 20;2(7621):614–615. doi: 10.1016/s0140-6736(69)90326-2. [DOI] [PubMed] [Google Scholar]
- Reed S. E., Bynoe M. L. The antiviral activity of isoquinoline drugs for rhinoviruses in vitro and in vivo. J Med Microbiol. 1970 May;3(2):346–352. doi: 10.1099/00222615-3-2-346. [DOI] [PubMed] [Google Scholar]
- Togo Y., Schwartz A. R., Hornick R. B. Failure of a 3-substituted triazinoindole in the prevention of experimental human rhinovirus infection. Chemotherapy. 1973;18(1):17–26. doi: 10.1159/000221243. [DOI] [PubMed] [Google Scholar]